Reprospher 200 C30-DE

Double Endcapped C30 Reversed-Phase Column for High Shape Selectivity

Reprospher 200 C30-DE is a high-performance reversed-phase HPLC column from Dr. Maisch HPLC GmbH, packed with ultra-pure, fully porous spherical silica (200 Å pore size) bonded with long-chain triacontyl ligands and double endcapped for maximum deactivation of residual silanol groups. This unique stationary phase provides exceptional shape selectivity, making it ideal for the separation of structural and geometric isomers, such as carotenoids and other long-chain hydrophobic molecules. The wide 200 Å pore structure allows efficient access for larger biomolecules, while the double endcapping ensures excellent peak symmetry, reproducibility, and column stability, even for challenging analytes.

Reprospher 200 C30-DE from Dr. Maisch HPLC GmbH offers exceptional selectivity and reproducibility – the ideal solution for laboratories focusing on isomer separations and hydrophobic biomolecules in advanced reversed-phase HPLC.

Key Features:

  • C30 long-chain reversed-phase with double endcapping – USP L62

  • 200 Å pore size for large molecules and biomacromolecules

  • Superior shape selectivity for structural and geometric isomers

  • Excellent peak shape for strongly hydrophobic analytes

  • Manufactured and QC-tested by Dr. Maisch HPLC GmbH

  • Available in 5 µm

Typical Applications:

  • Separation of carotenoids, retinoids, and fat-soluble vitamins

  • Analysis of geometric and positional isomers

  • Method development for highly hydrophobic biomolecules

  • Stability-indicating assays in pharmaceutical and food analysis

Specifications

Request Product
Particle Size
  • 5 µm
Pore Size 200 Å
Surface Area 160 m²/g
Phase/Modification C30
Particle Type
Separation Mode
USP Code
Endcapping Yes
Carbonload 10 %
pH Range 2 to 8

Material Number

Phase Material Number
Reprospher 200 C30-DE, 5 µm rs25.3de.
Reprospher 200 C18-TN Reprospher 200 Phenyl

Any questions?
We are here to help you.

info@dr-maisch.com +49 7073 5035 7

Follow us